Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on May 13, 2025
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
GlobeNewswire
·
May 13, 2025
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend …
Reflect Scientific Secures Patents for Data Center Cooling with Cryogenic Innovation
GlobeNewswire
·
May 13, 2025
OREM, Utah, May 13, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a leader in cryogenic technology, today announced a U.S. Patent for its innovative system to cool computer rooms using cryogenic methods. This development addresses the …
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
May 13, 2025
- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M - - Promising early signal in Cohort P with 90.5% high-grade recurrence free …
Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™
GlobeNewswire
·
May 13, 2025
The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second …
Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials
GlobeNewswire
·
May 13, 2025
Financing includes participation from Schooner Capital, Alexandria Venture Investments, and other existing investors Investment accelerates advancement of RPT1G, a novel NAMPT inhibitor, into a Phase 1/2 trial in patients with acute myeloid leukemia (AML) …
Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
GlobeNewswire
·
May 13, 2025
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
GlobeNewswire
·
May 13, 2025
WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today …
Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems
GlobeNewswire
·
May 13, 2025
Gold-Standard Technology Now Available in East Tennessee and Pacific Northwest Through Strategic Dual-Model Implementation Oak Ridge, TN, May 13, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor Corporation, the global leader in blood volume …
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
GlobeNewswire
·
May 13, 2025
Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid’s first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and …
Mindera Health™ announces publication of randomized, prospective clinical utility study demonstrating improved psoriasis patient outcomes
GlobeNewswire
·
May 13, 2025
Vista, CA, May 13, 2025 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, today announced positive results from the completion of a randomized, prospective clinical trial (MATCH) aimed at demonstrating the …
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
GlobeNewswire
·
May 13, 2025
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 13, 2025 (GLOBE …
Bionano Laboratories Announces Publication of the Largest Study To-Date Evaluating Clinical Utility of Optical Genome Mapping Across Multiple Hematologic Malignancies
GlobeNewswire
·
May 13, 2025
In 58% or 303 of 519 cases, optical genome mapping (OGM) revealed somatic aberrations that were not detected by the standard cytogenetic workup (SCGW), including Tier 1, Tier 2 and Tier 3 structural variants (SVs) and copy number variants (CNVs) In 15% or …
ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025
GlobeNewswire
·
May 13, 2025
GARDEN CITY, NY, May 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, announced today that they will be presenting first quarter 2025 financial …
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
GlobeNewswire
·
May 13, 2025
– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program – iTeos has initiated a …
Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
GlobeNewswire
·
May 13, 2025
Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced the initiation of …
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
GlobeNewswire
·
May 13, 2025
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“ …
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 13, 2025
Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Enrollment ongoing in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Strong financial position with approximately $462 …
BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights
GlobeNewswire
·
May 13, 2025
Achieved record quarterly sales of $11.5 million in Q1 2025, an increase of 27% compared to Q1 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.3 million, increasing by 519% and 81%, respectively, compared to Q1 of 2024 Shipped a …
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
GlobeNewswire
·
May 13, 2025
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative …
Knight to Present at the 2025 RBC Capital Markets Global Healthcare Conference in New York City
GlobeNewswire
·
May 13, 2025
MONTREAL, May 13, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a …